{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:33:11Z","timestamp":1794047591170,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.281850","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T03:30:52Z","timestamp":1677727852000},"page":"2261-2264","source":"Crossref","is-referenced-by-count":5,"title":["Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain"],"prefix":"10.3324","volume":"108","author":[{"given":"Pablo","family":"Galindo-Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Delgado-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Rodr\u00edguez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Puerta-Puerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"50863","doi-asserted-by":"crossref","unstructured":"Tsang M, Parikh SA. A concise review of autoimmune cytopenias in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2017; 12(1):29-38.","DOI":"10.1007\/s11899-017-0366-1"},{"key":"50864","doi-asserted-by":"crossref","unstructured":"Vitale C, Salvetti C, Griggio V. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood. 2021; 137(25):3507-3517.","DOI":"10.1182\/blood.2020008201"},{"key":"50865","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745-2760.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"50866","doi-asserted-by":"crossref","unstructured":"Vitale C, Montalbano MC, Salvetti C. Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs. Cancers (Basel). 2020; 12(2):282.","DOI":"10.3390\/cancers12020282"},{"key":"50867","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst B. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12):1107-1120.","DOI":"10.1056\/NEJMoa1713976"},{"key":"50868","doi-asserted-by":"crossref","unstructured":"Lacerda MP, Guedes NR, Yamakawa PE. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p). Ann Hematol. 2017; 96(9):1577-1578.","DOI":"10.1007\/s00277-017-3039-1"},{"key":"50869","doi-asserted-by":"crossref","unstructured":"Goede V, Fischer K, Busch R. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12):1101-1110.","DOI":"10.1056\/NEJMoa1313984"},{"key":"50870","doi-asserted-by":"crossref","unstructured":"Albiol N, Moreno C. Autoimmune cytopenia in CLL: prognosis and management in the era of targeted therapies. Cancer J. 2021; 27(4):286-296.","DOI":"10.1097\/PPO.0000000000000537"},{"key":"50871","doi-asserted-by":"crossref","unstructured":"Vitale C, Ahn IE, Sivina M. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016; 101(6):e254-258.","DOI":"10.3324\/haematol.2015.138289"},{"key":"50872","doi-asserted-by":"crossref","unstructured":"Gordon MJ, Maldonado E, Danilov AV. Refractory autoimmune cytopenias treated with venetoclax. Hemasphere. 2019; 3(3):e202.","DOI":"10.1097\/HS9.0000000000000202"},{"key":"50873","unstructured":"Carriles C, Ord\u00f3\u00f1ez-Fern\u00e1ndez L, Arias-Mart\u00ednez A, Men\u00e1rguez-Blanc R, Rosado-Mar\u00eda MC. Autoimmune hemolytic anemia, adverse event to venetoclax. Farm Hosp. 2019; 43(5):166-167."},{"key":"50874","doi-asserted-by":"crossref","unstructured":"Abdel-Samad N, Sughayar R. Can treatment with venetoclax for chronic lymphocytic leukemia (CLL) result in autoimmune hemolytic anemia?. Am J Case Rep. 2021; 22:e928514.","DOI":"10.12659\/AJCR.928514"},{"key":"50875","doi-asserted-by":"crossref","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017; 58(9):1-17.","DOI":"10.1080\/10428194.2017.1283032"},{"key":"50876","doi-asserted-by":"crossref","unstructured":"Thijssen R, Slinger E, Weller K. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015; 100(8):e302-306.","DOI":"10.3324\/haematol.2015.124560"},{"key":"50877","doi-asserted-by":"crossref","unstructured":"Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011; 96(5):752-761.","DOI":"10.3324\/haematol.2010.036152"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281850\/75424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281850\/75910","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11002\/75424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:39Z","timestamp":1794045819000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281850","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}